Global anemia treatment market is expected to generate around USD 40,915 million by 2025, growing at a CAGR of around 7.5% between 2019 and 2025. The high rate of nutritional deficiency is among the most important driving factors of the anemia treatment market.
The report analyzes and forecasts the anemia treatment market on a global and regional level. The study offers past data from 2017 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The report gives brief information about the drivers and restraints of the anemia treatment market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the anemia treatment market on a global level.
In order to give a transparent comprehensive view of the anemia treatment market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market.
The study provides a decisive view of the anemia treatment market is divided on the basis of anemia, drug, distribution channel, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Some key players of global anemia treatment market are Pfizer, Johnson and Johnson, Novartis, Roche, Amgen, Bayer, Glaxosmithkline, Teva Pharmaceuticals, Novo Nordisk, CSL, AMAG Pharmaceuticals, Rockwell Medicines, Akebia Therapeutics, and Vifor Pharma.
This report segments the global anemia treatment market into:
Global Anemia Treatment Market: Anemia Analysis
Global Anemia Treatment Market: Drug Analysis
Global Anemia Treatment Market: Distribution Channel Analysis
Global Anemia Treatment Market: Regional Analysis
Anemia is caused by the lack of red blood cells or hemoglobin in the human body. Red blood cells are responsible for carrying oxygen from lungs to rest of the body. Anemia symptoms include weakness, feeling tired, shortness of breath, and restrictions in physical activities, which may vary according to age, altitude, smoking habits, sex, and pregnancy status. Anemia, if left untreated, may even cause death. The main cause of anemia is various nutritional and non-nutritional factors, such as infectious diseases like malaria and tuberculosis.
According to the WHO, in 2018, about 56% of people globally were affected by anemia. Anemia can be effectively treated with a proper treatment method. The high rate of nutritional deficiency is among the most important driving factors of the anemia treatment market. According to the WHO, 50% of anemic cases are caused by iron deficiency due to low iron intake. Growing baby booming population and increasing chronic diseases and disorders are fuelling the anemia treatment market. Improper nutritional diet in underdeveloped countries also contributes to this market. According to the World Bank, anemia is the 8th major disease among young girls and women. Various government initiatives for improving the healthcare facilities in developing countries are also estimated to drive the anemia treatment market in the future. The continuous research and development activities related to anemia drugs and increasing anemia awareness in developing and undeveloped countries are estimated to create new growth opportunities in the anemia treatment market over the forecast period. However, medications of anemia drugs have adverse effects on the human body, which may hamper this market. For instance, patients with diabetes consuming iron for anemia may increase heart diseases among patients.
The anemia treatment market is fragmented on the basis of anemia, drug, and distribution channel. By anemia, the anemia treatment market includes iron deficiency, sickle cell, pernicious, thalassemia, and hemolytic. By drug, the market is divided into corticosteroids, gene therapy, bone marrow stimulants, iron chelating agents, immunotherapy, and supplements. On the basis of distribution channel, the anemia treatment market comprises e-commerce, hospital pharmacies, and retail pharmacies.
North America is projected to dominate the anemia treatment market globally, owing to the early introduction of highly developed treatment options, increasing nutritional deficiency due to changing lifestyle, and constant introduction of favorable reimbursement policies. The Asia Pacific anemia treatment market is anticipated to show a notable growth rate over the forecast time period.
Some key players of global anemia treatment market are Pfizer, Johnson and Johnson, Novartis, Roche, Amgen, Bayer, GlaxoSmithKline, Teva Pharmaceuticals, Novo Nordisk, CSL, AMAG Pharmaceuticals, Rockwell Medicines, Akebia Therapeutics, and Vifor Pharma.
Request the coronavirus impact analysis across industries and markets